India approves first dengue vaccine for individuals aged 4 to 60 years

📌 Summary:

• The Drug Controller General of India (DCGI) has granted market authorisation to Takeda Biopharmaceuticals India's QDENGA (TAK-003)

• This is the FIRST dengue vaccine ever approved in India

• Approved indication: prevention of dengue disease in individuals aged 4 to 60 years

• QDENGA is a live-attenuated TETRAVALENT vaccine — it is designed to protect against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, DENV-4)

• Dosing schedule: a two-dose regimen, with the doses administered three months apart

• Public health significance: dengue is endemic across most of India with recurring seasonal outbreaks; the tetravalent design matters because infection with one serotype gives only transient cross-protection, and a subsequent infection with a different serotype raises the risk of severe dengue

🎯 UPSC Relevance: GS2 (Health — public health governance, drug regulation) and GS3 (Science & Technology — vaccine technology, biotechnology applications). Useful for Mains answers on India's vector-borne disease burden, the National Vector Borne Disease Control Programme, and the regulatory pathway for new vaccines.

📝 Prelims Facts:

• Vaccine: QDENGA (TAK-003), developed by Takeda

• Approving authority: Drug Controller General of India (DCGI), who heads the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare

• Type: live-attenuated tetravalent vaccine

• Age indication: 4 to 60 years; two doses, three months apart

• Dengue is caused by a Flavivirus with four serotypes (DENV-1 to DENV-4), transmitted mainly by the Aedes aegypti mosquito

• Aedes aegypti is a daytime biter and also transmits chikungunya, Zika and yellow fever

🔑 Key Term: Tetravalent Vaccine — a vaccine formulated to generate immunity against four distinct strains or serotypes of a pathogen simultaneously; essential for dengue because immunity to one serotype does not protect against the other three and may worsen a later infection.